Table 8.
Clinician Knowledge of Disease Pathophysiology and Emerging Therapies
| PCP (n = 318) | Hepatology (n = 57) | Gastroenterology (n = 156) | Endocrinology (n = 98) | |
|---|---|---|---|---|
| Which of the following processes are involved in the pathophysiology of NASH? (select all that apply) | ||||
| Insulin resistance | 68% | 95% | 89% | 84% |
| Oxidative stress | 45% | 81% | 71% | 75% |
| Proinflammatory cytokine production | 54% | 79% | 72% | 73% |
| Impaired GLP-1 secretion | 43% | 56% | 51% | 34% |
| Increased glucagon levels | 35% | 26% | 31% | 30% |
| De novo hepatic lipogenesis | 35% | 60% | 45% | 55% |
| Other | 0 | 4% | 1% | 0% |
| Unsure | 19% | 0% | 6% | 7% |
| How useful do you think GLP-1 receptor agonists are for each of the following?* | ||||
| Improving glycemic control | 4.0 | 4.0 | 3.7 | 4.4 |
| Improving cardiovascular outcomes | 3.6 | 3.4 | 3.4 | 4.1 |
| Improving microvascular outcomes | 3.6 | 3.5 | 3.3 | 3.7 |
| Assisting in weight loss | 3.4 | 3.2 | 3.2 | 4.1 |
| Decreasing mortality | 3.5 | 3.2 | 3.2 | 3.8 |
| Improving liver histology in NASH | 3.2 | 3.1 | 3.1 | 3.5 |
| How familiar are you with each of the following investigational therapies for NASH? † | ||||
| Aldafermin | 1.2 | 1.9 | 1.4 | 1.2 |
| Aramchol | 1.2 | 2.0 | 1.4 | 1.3 |
| Belapectin | 1.2 | 1.7 | 1.4 | 1.3 |
| Cenicriviroc | 1.2 | 2.6 | 1.7 | 1.3 |
| Cilofexor | 1.2 | 2.3 | 1.5 | 1.4 |
| Efruxifermin | 1.2 | 1.7 | 1.4 | 1.3 |
| Firsocostat | 1.2 | 1.9 | 1.4 | 1.4 |
| Lanifibranor | 1.2 | 2.3 | 1.6 | 1.4 |
| Obeticholic acid | 1.5 | 3.8 | 3.2 | 1.8 |
| Resmetirom | 1.2 | 2.2 | 1.6 | 1.4 |
| Semaglutide | 2.2 | 3.2 | 2.3 | 4.0 |
Notes: *Means of 1–5 scale: 1 = not at all useful, 5 = extremely useful. Respondents selecting unsure were excluded. †Means of 1–5 scale: 1 = not at all familiar, 5 = extremely familiar.